MorphoSys AG has named Markus Enzelberger as chief scientific officer. He has served as interim CSO since April. Dr Enzelberger succeeds Marlies Sproll, who has resigned for family reasons, but will assume a part-time position as a special advisor to the chief executive, Simon Moroney.
Dr Enzelberger joined MorphoSys in 2002 and since that time has co-invented two of the company’s proprietary antibody libraries and worked on multiple discovery programmes including guselkumab, the recently approved treatment for plaque psoriasis which was developed by Janssen Biotech Inc.
Prior to joining MorphoSys, Dr Enzelberger, a chemist by training, worked at the California Institute of Technology on the core technology of Fluidigm Corp of the US.
MorphoSys announced the appointment on 30 October 2017.
Copyright 2017 Evernow Publishing Ltd